Skip to main content
SpringerLink
Log in

Instabile Angina pectoris und akuter Myokardinfarkt

  • Chapter
HerzAkutMedizin

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur zu Kapitel 2.1

  1. ACC/AHA Guidelines for Exercise Testing: Executive Summary (1997) A report of the American College of Cardiology/American Heart Association Task Force on Practise Guidelines (Committee on Exercise Testing). Circulation 96:345–354

    Google Scholar 

  2. AIRE (The Acute Infarction Ramipril Efficacy) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–828

    Google Scholar 

  3. Ambronsioni E, Borghi C, Manani B (1995) The effect of the antiotensin converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 322:80–85

    Article  Google Scholar 

  4. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death myocardial infarction, and stroke by prolonged antiplatele therapy in various categories of patients. BMJ 308:81–106

    Google Scholar 

  5. Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86

    Article  Google Scholar 

  6. Antman EM (1994) Hirudin in acute myocardial infarction safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 90:1624–1630

    PubMed  CAS  Google Scholar 

  7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 12; 100(15):1593–1601

    CAS  Google Scholar 

  8. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators (2001) Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358(9282):605–613

    Article  Google Scholar 

  9. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 316: 1337–1343

    PubMed  CAS  Google Scholar 

  10. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, de Torbal A, Amstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML (2002) Platet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359:189–197

    Article  PubMed  CAS  Google Scholar 

  11. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, Chrolavicius S, Hunt D, Keltai M, Franzosi MG; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators (2002) Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106(13):1622–1626

    Article  PubMed  Google Scholar 

  12. Bugiardini R, Bairey Merz CN (2005) Angina with „normal“ coronary arteries: a changing philosophy. JAMA 293(4):477–484

    Article  PubMed  CAS  Google Scholar 

  13. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, Holder DA, Joblonsky G, Kostuk WJ, Melendes LJ, Myers MG (1988) Aspirin, sulfinpyrazone or both to treat acute unstable angina. N Engl J Med 313:1369–1375

    Article  Google Scholar 

  14. Cannon CP, McCabe CH, Henry TC, Schweiger MJ, Gibson RS, Müller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E (1994) A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993–1003

    PubMed  CAS  Google Scholar 

  15. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, Topol EJ (2001) Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 20; 103(7):961–966

    CAS  Google Scholar 

  16. Dati F, Hänseler E, Hohnloser S, Hubl W, Katz N, Messinger M, Puschendorf B, Stein W (1997) Empfehlungen zur Laboratoriumsdiagnostik bei akuten ischämischen Herzerkrankungen. J Lab Med 21:402–408

    Google Scholar 

  17. De Vreede JM, Gorgels APM, Verstraaten GMP, Vermeer F, Dassen WRM, Wellens HJJ (1991) Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol 18:698–706

    Article  PubMed  Google Scholar 

  18. Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ (1998) Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the prevention of ischemic complications. Evaluation of PTCA to improve long-term outcome with abciximab GP-IIb-/IIIa receptor blockade. J Am Coll Cardiol 32(6):1619–1623

    Article  PubMed  CAS  Google Scholar 

  19. Ellis K, Tcheng JE, Sapp S, Topol EJ, Lincoff AM, (2003) Mortality Benefit of beta blockade in patient with acute coronary syndromes undergoing coronary intervention: pooled results from the epic, epilog, epistent, capture and rapport trials. J Interv Cardiol 16:299–305

    Article  PubMed  Google Scholar 

  20. Gipson RS, Boden WE, Théroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE (1986) Diltiazem and reinfaction in patients with non-Q wave myocardial infarction. Results of a double-blind, randomized multicenter trial. N Engl J Med 315:423–429

    Article  Google Scholar 

  21. Granger CB, Califf RM, Topol EJ (1992) Review of thrombolytic therapy for acute myocardial infarction. Drugs 44:293–325

    PubMed  CAS  Google Scholar 

  22. Gottwik M, Zahn R, Schiele R, Schneider S, Gitt AK, Fraunberger L, Bossaller C, Glunz HG, Altmann E, Rosahl W, Senges J; Myocardial Infarction Registry (MIR)-Study Groups (2001) Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology; results from the pooled data of the maximal individual therapy in acute myocardial infarction (MITRA 1+2) registries and the myocardial infarction registry (MIR). Eur Heart J 22(19):1794–1801

    Article  PubMed  CAS  Google Scholar 

  23. Hamm CW (2004) Guidelines: acute coronary syndrome (ACS). I: Acute coronary syndrome with ST-elevation. Z Kardiol 93:72–90

    Article  PubMed  CAS  Google Scholar 

  24. Hamm CW (2004) Guidelines: acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation. Z Kardiol 93:324–341

    Article  PubMed  CAS  Google Scholar 

  25. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T (1997) Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N Engl J Med 337:1648–1653

    Article  PubMed  CAS  Google Scholar 

  26. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O’Connor CM, Vorchheimer DA, Guyatt GH (2004) Antithrombotic therapy for coronary artery disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):S513–S548

    Article  Google Scholar 

  27. Harrington RA (1997) Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet glycoprotein IIb-IIIa in unstable angina: receptor suppression using integrelin therapy. Am J Cardiol 80(4A):34B–38B

    Article  PubMed  CAS  Google Scholar 

  28. Held PH, Yusuf S (1989) Early intravenous beta-blockade in acute myocardial infarction. Cardiology 76:132–143

    Article  PubMed  CAS  Google Scholar 

  29. Held PH, Yusuf S, Furberg CD (1989) Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 299:1187–1192

    Article  PubMed  CAS  Google Scholar 

  30. Herlitz J, Emanuelsson H, Swedberg K. Vedin A, Waldenstrom A, Waldenstrom J, Hjalmarson A (1984) Göteborg metoprolol trial. Enzyme-estimated infarct size. Am J Cardiol 53:15D–21D

    Article  PubMed  CAS  Google Scholar 

  31. Hoet B, Falcon C, De Reys S, Arnout J, Deckmyn H, Vermylen J (1990) R68070, a combined thromboxane/endoperoxide receptor antagonist and thromboxane synthase inhibitor, inhibits human platelet activation in vitro and in vivo: a comparison with aspirin. Blood 75:646–653

    PubMed  CAS  Google Scholar 

  32. Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, Sutton G, Fox K (1994) Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 24:39–45

    PubMed  CAS  Google Scholar 

  33. Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schomig A, Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators (2004) Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA 291(8):947–954

    Article  PubMed  CAS  Google Scholar 

  34. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van-der-Meer J, Olaisson E, Undeland S, Ludwig K (1997) Comparison of low-molecular-weight heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation 96:61–68

    PubMed  CAS  Google Scholar 

  35. Lee IV (1995) Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 6 trial. Am J Cardiol 75:7–13

    Article  PubMed  CAS  Google Scholar 

  36. Kuch B, Bolte HD, Hoermann A, Meisinger C, Loewel H (2002) What is the real hospital mortality from acute myocardial infarction? Epidemiological vs clinical view. Eur Heart J 23(9):714–720

    Article  PubMed  CAS  Google Scholar 

  37. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBattiste PM, Yeung AC (2003) Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiografic outcomes: results of the tirofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial. Circulation 107(11):1497–1501

    Article  PubMed  Google Scholar 

  38. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289(7):853–863

    Article  PubMed  CAS  Google Scholar 

  39. Lidón RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Lévesque J (1994) A pilot, early angiografic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89:1567–1572

    PubMed  Google Scholar 

  40. MacMahon S, Collins R, Knight C, Yusuf S (1988) Reduction in major morbidity and mortality by heparin in acute myocardial infarction. Circulation 78(suppl II):II-389(A)

    Google Scholar 

  41. Magnesium in Coronaries (MAGIC) Trial Investigators (2002) Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the magnesium in coronaries (MAGIC) trial: a randomised controlled trial. Lancet 360(9341):1189–1196

    Article  Google Scholar 

  42. Mark DB, Cowper PA, Berkowitz SD, Davidson RL, DeLong ER, Turpie AG, Califf RM, Weatherley B, Cohen M (1998) Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Eficacy and and safety of subcutaneous enoxaparin in non-Q wave coronary events (unstable angina or non-Q-wave myocardial infarction). Circulation 97:1702–1707

    PubMed  CAS  Google Scholar 

  43. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281):527–533

    Article  PubMed  CAS  Google Scholar 

  44. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman SD, Wilcox RG, Schunemann HJ, Ohman EM (2004) Thrombolysis and adjunctive therapy in acute myocardial infarction: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(3 Suppl):S549–S575

    Article  Google Scholar 

  45. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ (1998) Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. Global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO-IIb) investigators. J Am Coll Cardiol 31(7):1493–1498

    Article  PubMed  CAS  Google Scholar 

  46. Moliterno DJ, Harrington RA, Krucoff MW, Armstrong PW, Van de Werf F, Kristinsson A, Hul W, Paraschos, Bhakar M, Rames A, Topol EJ (1996) More complete and stable reperfusion with platelet IIb/IIIa antagonism plus thrombolysis for AMI: the PARADIGM trial. Circulation 94(Suppl I):I-553 (A)

    Google Scholar 

  47. Neuhaus KL, v. Essen R, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kalhammer E, Simon H, Horacek T (1994) Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft leitender kardiologischer Krankenhausärzte (ALKK). Circulation 90:1638–1642

    PubMed  CAS  Google Scholar 

  48. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, Anderson HV, Ellis SG, Cohen MD, Spriggs D, Miller M, Kereiakes D, Yakubov S, Kitt MM, Sigmon KM, Califf RM, Krucoff MW, Topol EJ (1997) Combined accelerated tissue-plasminogen activiator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrelin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. Circulation 95:846–854

    PubMed  CAS  Google Scholar 

  49. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327:669–677

    Article  PubMed  CAS  Google Scholar 

  50. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI (2004) Antithrombotic therapy during percutaneous coronary intervention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(suppl 3):S576–S599

    Article  Google Scholar 

  51. Pursuit Trial Investigator (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N Engl J Med 339(7):436–443

    Google Scholar 

  52. Rouslathi E (1991) Integrins. J Clin Invest 87:1–5

    Article  Google Scholar 

  53. Simoons ML; GUSTO IV-ACS Investigators (2001) Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357(9272):1915–1924

    Article  PubMed  CAS  Google Scholar 

  54. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators (2002) Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 28; 346(13):957–966

    Article  PubMed  CAS  Google Scholar 

  55. Swedberg K, Held P, Kjekhus J, Rasmussen K, Ryden L, Wedel H (1992) Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: results of the cooperative north Scandinavian enalapril survival study II (CONSENSUS II). N Engl J Med 327:678–684

    Article  PubMed  CAS  Google Scholar 

  56. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW, CADILLAC Investigators (2003) Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Circulation 108(ll):1316–1323

    Article  PubMed  CAS  Google Scholar 

  57. Telford AM, Wilson C (1981) Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1:1225–1228

    Article  PubMed  CAS  Google Scholar 

  58. Teo KK, Yusuf S (1993) Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. Drugs 46:347–359

    PubMed  CAS  Google Scholar 

  59. The CAPTURE Investigators (1997) Randomized placebo-controlled trial abciximab before and during coronary intervention in refractory unstable angina. Lancet 349:1429–1435

    Google Scholar 

  60. The Danish Study Group of Verapamil in Myocardial Infarction (1984) Verapamil in acute myocardial infarction. Eur Heart J 5:516–528

    Google Scholar 

  61. The EPIC Investigators (1994) Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med 330:956–961

    Google Scholar 

  62. The EPILOG Investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularisation. N Engl J Med 336:1689–1696

    Google Scholar 

  63. The Frisc Study Group (1996) Low-molecular-weight heparin during instability in coronary artery disease. Lancet 347:561–568

    Google Scholar 

  64. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631–1637

    Google Scholar 

  65. The Gruppo Italiano per Io Studio della Sopravvivenza nell’Infarto Miocardico GISSI-3 (1994) Effects of lisinopril and transdermal glyeryl trinitrate singly and together of 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343:1115–1122

    Google Scholar 

  66. The GUSTO Investigators (1993) An international rendomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Google Scholar 

  67. The Holland Interuniversity Nifedipine/ Metoprolol Trial (HINT) Research Group (1986) Early treatment of unstable angina in coronary care unit: a randomized, double-blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J 56:400–413

    Google Scholar 

  68. The IMPACT-II Investigators (1997) Randomized placebo-controlled trial of effect of eptifibatide on complications on percutaneous coronary intervention. Lancet 349:1422–1428

    Google Scholar 

  69. The ISIS-1 (First International Study of Infarct Survival) Collaborative Group (1986) Randomized trial of intravenous atenolol among (16 027) cases of suspected acute myocardial infarction: ISIS-1. Lancet ii:57–65

    Google Scholar 

  70. The ISIS-2 (Second international Study of Infarct Survival) Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet ii:349–360

    Google Scholar 

  71. The ISIS-3 (Third International Study of Infarct Survival Collaborative) Study Group (1992) A randomised comparison of streptokinase versus tissue plasminogen activator versus antistreplase and of aspirin plus heparin versus aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 339:753–770

    Article  Google Scholar 

  72. The ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995) ISIS-4: a randomized factorial trial assessing early captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345:669–685

    Article  Google Scholar 

  73. The Israeli Sprint Study Group (1988) Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 9:354–364

    Google Scholar 

  74. The MIAMI Trial Research Group (1985) Development of myocardial infarction. Am J Cardiol 56:23G–26G

    Article  Google Scholar 

  75. The Multicenter Diltiazem Postinfarction Trial Research Group (1988) The effect of diltiazem on mortality and reinfarction after Myocardial infarction. N Engl J Med 319:385–392

    Article  Google Scholar 

  76. The Paragon Investigators (1998) International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIB/IIIa inhibitor) heparin or both in unstable angina. Circulation 97:2386–2395

    Google Scholar 

  77. The Prism Plus Study Investigators (1998) Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 338:1488–1497

    Google Scholar 

  78. The Prism Study Investigators (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338:1498–1505

    Google Scholar 

  79. The SCATI Group (1989) Randomized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 2:182–186

    Google Scholar 

  80. The RAPT Investigators (1994) Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The ridogrel versus aspirin patency trial (RAPT). Circulation 89:588–595

    Google Scholar 

  81. The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336:827–830

    Article  Google Scholar 

  82. Théroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G, Pelletier E, Juneau M, Stasiak J, deGuise P (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319:1105–1111

    Article  PubMed  Google Scholar 

  83. Topol EJ; GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357(9272):1905–1914

    Article  PubMed  CAS  Google Scholar 

  84. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J (1994) Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 89:1557–1566

    PubMed  CAS  Google Scholar 

  85. Tran H, Anand SS (2004) Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 292(15): 1867–1874

    Article  PubMed  CAS  Google Scholar 

  86. White H; Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators (2001) Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358(9296):1855–1863

    Article  PubMed  CAS  Google Scholar 

  87. Woods KL, Fletcher S, Roffe C, Haider Y (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester intravenous magnesium intervention trial (LIMIT-2). Lancet 339:1553–1558

    Article  PubMed  CAS  Google Scholar 

  88. Yusuf S, Collins R, MacMahon S, Peto R (1988) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomized trials. Lancet 1:1088–1092

    Article  PubMed  CAS  Google Scholar 

  89. Yusuf S, Sleight P, Held P, McMahon S (1990) Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. Circulation 82(3 Suppl):II 117–134

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik, Campus Charité Mitte, Charité Universitätsmedizine Berlin, Schumannstr. 20/21, 10117, Berlin

    Prof. Dr. med. K. Stangl

Authors
  1. Prof. Dr. med. K. Stangl
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Herz- und Thoraxchirurgie, Universitätsspital Basel, Spitalstr. 21, 4031, Basel, Schweiz

    H. -R. Zerkowski

  2. Medizinische Klinik mit Schwerpunkt Kardiologie, Angiologie und Pneumologie, Campus Charité Mitte, Charité-Universitätsmedizin Berlin, Schumannstr. 20/21, 10117, Berlin

    G. Baumann

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Steinkopff Verlag Darmstadt

About this chapter

Cite this chapter

Stangl, K. (2006). Instabile Angina pectoris und akuter Myokardinfarkt. In: Zerkowski, H.R., Baumann, G. (eds) HerzAkutMedizin. Steinkopff. https://doi.org/10.1007/3-7985-1630-8_13

Download citation

  • DOI: https://doi.org/10.1007/3-7985-1630-8_13

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1505-5

  • Online ISBN: 978-3-7985-1630-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation